Cleveland Clinic The New Age of Alzheimer’s Disease Therapeutics 2025

The introduction of anti-amyloid therapies as a new class of treatment for Alzheimer’s Disease (AD) has brought significant advances in the care of patients with mild cognitive impairment (MCI) and early-stage AD. However, healthcare providers, especially neurologists, face numerous challenges in integrating these therapies into clinical practice. These include uncertainties regarding patient selection, pre-authorization and insurance processes, infusion logistics, management of potential side effects like ARIA (amyloid-related imaging abnormalities), and determining the appropriate duration and frequency of treatment.
The goal of this program is to provide healthcare professionals with the necessary tools, knowledge, and resources to confidently navigate these challenges. The conference will address critical aspects of anti-amyloid therapies in clinical practice, including cognitive assessment, patient selection, the pre-authorization process, infusion logistics, and the management of side effects like ARIA.
This conference will also foster greater collaboration between neurologists and primary care physicians (PCPs), enabling early recognition and screening for AD and MCI, ultimately improving patient outcomes by accelerating the anti-amyloid treatment process.
TARGET AUDIENCE
This activity is designed for neurologists, primary care physicians (PCPs), internists, geriatricians, nurse practitioners, nurses, and other healthcare providers involved in the diagnosis, management, and treatment of patients with Alzheimer’s Disease or MCI.
LEARNING OBJECTIVES
Upon completion of this program, participants will be able to:

Describe the clinical effects of anti-amyloid therapies and be able to convey to patients.
Identify patients that are candidates for anti-amyloid therapies.
Recognize and monitor the potential complications of anti-amyloid therapies.
List the administrative steps necessary to prescribe anti-amyloid therapies.

 
+ Topics:

01 Background on antiamyloid therapies Charles Bernick, MD, MPH
02 Translating clinical trial results to the clinic Babak Tousi, MD
03 Who is the right patient for anti-amyloid therapies Lakeshia Gibson, MD
04 Surveillance for amyloid-related imaging abnormalities (ARIA) Dylan Wint, MD
05 Logistics of starting anti-amyloid therapy Maileen Ulep, PhD, MSN, APRN, FNP-BC